Oxurion NV operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Oxurion NV with three other
miscellaneous service companies in Europe:
Redx Pharma PLC
of UNITED KINGDOM
sales of £3.13 million [US$4.19 million]
of which 100%
SyntheticMR AB (publ)
(45.80 million Swedish Kronor [US$5.39 million]
Avacta Group Plc
based in UNITED KINGDOM
(£3.89 million [US$5.21 million]
of which 60%
was Life Sciences).
During the year ended December of 2019, sales at
Oxurion NV were 3.95 million Euro (US$4.70 million).
decrease of 25.8%
versus 2018, when the company's sales were 5.32 million Euro.